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Creatine supplementation decreases homocysteine in an ani-
mal model of uremia.
Background. Hyperhomocysteinemia is prevalent in more
than 85% of patients with end-stage renal disease (ESRD) and
is thought to contribute to the excess cardiovascular mortality
and morbidity. Creatine is synthesized by methylation of gua-
nidinoacetate with formation of S-adenosylhomocysteine and
subsequently, homocysteine (Hcy). Creatine supplementation
down-regulates its endogenous synthesis and, thus, may reduce
Hcy production. The present study investigates the effect of
creatine supplementation on Hcy concentrations in an animal
model of uremia.
Methods. Male Wistar rats were either sham-operated and
received a control diet (N 8) or a 2% creatine-supplemented
diet (N 8), or underwent subtotal nephrectomy and received
a control diet (N 10) or a 2%-supplemented creatine diet (N
10). After 2 weeks of treatment, total plasma Hcy, creatine,
creatinine, folate, and vitamin B12 were determined, as well as
hepatic folate and vitamin B12 concentrations.
Results. Plasma creatinine concentrations were higher in ne-
phrectomized animals, but similar in creatine-supplemented
and control diet–fed animals. Plasma Hcy was higher in ne-
phrectomized animals but lower in creatine-supplemented ne-
phrectomized animals compared to nephrectomized control
diet–fed animals (12.1  2.4 mol/L vs. 15.4  1.7 mol/L;
P  0.01). Total plasma Hcy inversely correlated with plasma
creatine concentrations (r0.39; P 0.02). Plasma folate was
higher in supplemented animals and hepatic tetrahydrofolate
(THF) was higher in nephrectomized supplemented animals.
Plasma vitamin B12 was similar in all groups, whereas hepatic
vitamin B12 was higher in nephrectomized animals.
Conclusion. Creatine supplementation can effectively lower
plasma Hcy concentrations in an animal model of uremia and
should be further investigated as a potential treatment for
hyperhomocysteinemia in patients with ESRD.
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Hyperhomocysteinemia is considered an independent
risk factor for cardiovascular disease in the general popu-
lation, as well as in patients with end-stage renal disease
(ESRD) [1, 2]. About 85% of patients with renal failure
have hyperhomocysteinemia, eventually contributing to
the excess cardiovascular mortality in this population
[3]. The mechanism underlying hyperhomocysteinemia
in ESRD is poorly understood. Homocysteine (Hcy) [2]
is a sulfur-containing amino acid, formed by demethyl-
ation of methionine and plays an important role in the
activated methyl and folate cycle (Fig. 1). Methionine
can intracellularly be converted to S-adenosylmethionine,
a sulfonium compound with a highly reactive methyl group,
which acts as a universal methyl donor in numerous
transmethylation reactions in vivo. The demethylated
product S-adenosyl homocysteine, a thioether, is readily
hydrolyzed to Hcy and adenosine by S-adenosyl homo-
cysteine hydrolase. Hcy metabolism is nutritionally regu-
lated. In conditions with high methionine concentrations,
the transsulfuration pathway is favored, in which Hcy
condenses with serine to cystathionine, which is further
metabolized to cysteine and sulfate. In conditions of low
methionine intake, remethylation of Hcy to methionine
occurs through methyl donation from 5-methyltetrahy-
drofolate (5-CH3THF) by means of methionine synthase.
Vitamin B12 acts as a cofactor in this remethylation path-
way. 5-CH3THF is demethylated to tetrahydrofolate
(THF), which is reconverted to 5-CH3THF in a multiple-
step folate cycle with serine glycine conversion by means
of the methylene tetrahydrofolate reductase. Treatment
of hyperhomocysteinemia mainly consists of alimentary
folic acid and vitamin B6 and B12 supplements. An aver-
age reduction of about 30% in plasma total Hcy (tHcy)
is observed in uremic patients treated with folic acid [3].
The effect of vitamin B6 and B12 is in general much less
pronounced [3]. A randomized analysis by Bostom et al
[4] reported a decrease of 12% in fasting plasma tHcy
with vitamin B6 supplementation. Vitamin B12 supple-
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Fig. 1. Overview of homocysteine and creatine metabolism. Methionine is converted to S-adenosylmethionine, which is demethylated to S-adenosyl-
homocysteine by methyltransferases. Creatine is formed by methylation of guanidinoacetate, which is synthesized from glycine and arginine.
Creatine supplementation decreases guanidinoacetate synthesis by repressing AGAT biosynthesis and consequent reduction of guanidinoacetate
formation. Homocysteine is either remethylated to methionine or degraded in the transsulfuration pathway. Abbreviations are: AGAT, arginine:gly-
cine amidinotransferase (EC 2.1.4.1); THF, tetrahydrofolate; 5CH3-THF, 5-methyltetrahydrofolate; 5,10-CH2-THF: 5,10 methylene tetrahydrofolate;
Ser, serine; Gly, glycine.
mentation lowered tHcy concentration with 35%, only in
dialysis patients with low cobalamin status [5]. However,
even combined high-dose folic acid and vitamin B6 or
B12 supplementation cannot entirely normalize tHcy in
ESRD patients [3]. Supplementation with other methyl-
donating molecules such as betaine can decrease post-
methionine loading tHcy concentrations by 18%, in addi-
tion to folic acid supplementation [6]. Additional tHcy
lowering therapies are required in preventing excess car-
diovascular mortality in these patients.
Creatine is increasingly popular as an ergogenic sup-
plement in an athletic population [7–9]. Dietary intake
and endogenous synthesis in liver compensate for a daily
loss as creatinine of about 2%. Creatine is synthesized in
mammals through two successive metabolic steps (Fig. 1).
First, guanidinoacetate is formed in the kidney from gly-
cine and arginine by arginine:glycine amidinotransferase
(AGAT) (EC 2.1.4.1). Second, guanidinoacetate is meth-
ylated in the mammalian liver to creatine by guani-
dinoacetate methyltransferase (GAMT) (EC 2.1.1.2)
with S-adenosylmethionine acting as methyl donor [8].
Creatine supplementation down-regulates endogenous
creatine synthesis by repression of AGAT biosynthesis
and consequent guanidinoacetate formation (Fig. 1).
Mudd and Poole [10] and Mudd, Ebert, and Scriver
[11] calculated that methylation of guanidinoacetate dur-
ing creatine biosynthesis accounted for up to 70% of the
transmethylation reactions in the body. Quantitatively,
this exceeds all other methylation reactions. Stead et al
[12] demonstrated that down-regulation of endogenous
creatine synthesis by creatine supplementation could de-
crease methylation demand and tHcy in animals with
normal renal function. Whether creatine can also lower
tHcy in conditions of renal failure is presently unknown.
The present study investigates the effect of creatine
supplementation on tHcy concentrations in both animals
with uremia and normal kidney function.
METHODS
Animal procedures
Male Wistar rats weighing 200 to 230 g were obtained
from Iffa Credo (Brussels, Belgium). All animal care
was in accordance with local prescriptions and the NIH
Guide for the Care and Use of Laboratory Animals.
Renal failure was induced using a standard procedure
of subtotal nephrectomy as described before [13, 14].
Rats were anesthetized with halothane (Fluothane) (As-
tra-Zeneca, Destelbergen, Belgium) and a flank incision
was made exposing the kidney. The upper and lower
poles of the left kidney were cryoablated, followed 1
week later by a right nephrectomy. The sham procedure
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consisted of a flank incision and manipulation of the
kidney without tissue destruction.
Animals were randomly allocated to four groups: (1)
sham-operated, control diet (N 8); (2) sham-operated,
creatine-supplemented diet (N  8); (3) subtotal ne-
phrectomized, control diet (N  10); and (4) subtotal
nephrectomized, creatine-supplemented diet (N  10).
The animals had free access to food and drinking water.
Creatine supplementation was started 1 week after
the last surgical procedure by addition of 2% creatine
monohydrate (wt/wt) (Sigma Chemical Co., St. Louis,
MO, USA) to the control diet. Control animals were
kept on a soy-based maintenance diet (RM1) (Special
Diet Services, Witham, UK), containing 14% protein.
Urine and blood samples were collected at the start
and after 14 days of creatine supplementation. Body
weight and individual food intake were recorded on these
occasions. Folate intake was calculated from food intake.
Biochemical determinations
Creatinine clearances. Plasma and urinary creatinine
concentrations were determined enzymatically (Roche Di-
agnostics, Mannheim, Germany) on a Modular P analyzer
(Roche Diagnostics) according to the manufacturer’s pro-
cedure. Creatinine clearances were calculated based upon
24-hour urine collections. Plasma urea concentrations
were determined enzymatically (Roche Diagnostics).
Total plasma Hcy concentrations were determined us-
ing a fluorescence polarization immunoassay on an Ax-
sym analyzer (Abbott Laboratories, Abbott Park, IL,
USA).
Plasma folate and plasma and hepatic vitamin B12 con-
centrations were determined using an electrochemilum-
inescence assay (Roche Diagnostics) on an Elecsys 2010
Analyzer (Roche Diagnostics). Plasma and urine creatine
concentrations were determined enzymatically as de-
scribed before [15]. Total intramuscular creatine concentra-
tions (mol/wet weight) were determined colorimetrically
according to Berlet [16]. Urinary sulfate was determined
colorimetrically using barium chloranilate according to
Bertolacini and Barney [17]. Hepatic nonsubstituted THF
and 5-CH3THF (monoglutamates) were determined us-
ing high-pressure liquid chromatography (HPLC) with
fluorometric detection as described before [18]. Samples
were homogenized in 50 mmol/L acetate buffer (pH 4.9)
(2% ascorbic acid and 1% 2-mercaptoethanol), deconju-
gated using rat plasma and heated for 5 minutes in boiling
water. Samples were flushed with nitrogen between ev-
ery manipulation. The analysis was performed on Gilson
307 HPLC pump (Gilson Int., Den Haag, The Nether-
lands) with a Gilson 122 fluorometric detector (ex, 295
nm; em, 356 nm) using a Chrompack Spherisorb 3 ODS-2
reversed-phase column. Recoveries were 86% and 93%
for THF and 5-CH3THF, respectively.
Statistics
Data are expressed as mean  SD. One-sample Kol-
mogorov-Smirnov test was used to pretest normal distri-
bution. Student t test was used to compare separate
groups when appropriate. Differences were considered
significant at P less than 0.05. Correlation between pa-
rameters was examined using Spearman rank correlation
analysis.
RESULTS
Biometrical and biochemical characteristics
Subtotal nephrectomized animals exhibited lower
body mass and renal function indices compared to sham-
operated animals. No significant differences in body weight,
food, or folate intake were observed between creatine-
supplemented and control diet–fed groups in either sub-
total nephrectomized or sham-operated groups (Table 1).
Creatinine clearance rates were similar in creatine-sup-
plemented and control diet–fed animals (Table 1). Plasma
creatine and urinary creatine excretion was significantly
higher in creatine-supplemented animals. Total intra-
muscular creatine concentrations were similar in ne-
phrectomized and sham-operated animals [34.5  2.6
mol/g vs. 34.8  3.3 mol/g; P  NS (pooled data)],
but higher concentrations were observed in creatine-
supplemented animals than in control diet–fed animals
[36.1  2.8 mol/g vs. 33.0  2.0 mol/g; P  0.001
(pooled data)]. Urinary sulfate excretion did not differ
between creatine-supplemented and control diet–fed an-
imals.
Plasma tHcy concentrations
Subtotal nephrectomized, control diet–fed animals had
higher tHcy concentrations compared to sham-operated
control diet–fed animals (Fig. 2). Lower tHcy concentra-
tions were observed in nephrectomized creatine-supple-
mented animals compared to nephrectomized control
diet–fed animals (Fig. 2). In sham-operated animals, only a
tendency toward lower tHcy concentrations was observed.
Pooled data from sham-operated and nephrectomized
animals demonstrated significant lower tHcy concentra-
tions in the creatine-supplemented groups compared to
the control diet–fed group (12.4  2.2 mol/L vs. 14.6 
1.9 mol/L; P  0.005).
Plasma tHcy concentrations inversely correlated with
plasma creatine concentrations (r  0.39; P  0.02)
(Fig. 3), as well as with total intramuscular creatine con-
centrations (r  0.35; P  0.05). tHcy concentrations
correlated significantly with creatinine clearance in con-
trol diet–fed animals (r  0.68; P  0.005), but the
correlation was lost in creatine-supplemented animals (r
0.06; P  NS) (Fig. 4). No correlation between tHcy
and urinary sulfate excretion was observed.
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Table 1. Comparative biometric characteristics, baseline glomerular filtration markers, and biochemical parameters in control diet
(soy-based) and creatine-supplemented (2% wt/wt) diet–fed animals, with or without preexisting renal failure
Sham-operated Subtotal nephrectomized
Control diet Creatine diet Control diet Creatine diet
(N  8) (N  8) (N  10) (N  10)
Body weight g 36321 37219 33117a 34120a
Food intake g/day 171 184 183 175
Folate intake mg/day 0.0170.001 0.0180.004 0.0180.003 0.0170.005
Plasma creatinine lmol/L 20.03.4 20.03.9 50.77.8a 48.49.0a
Plasma urea-N mmol/L 10.72.5 11.81.4 21.14.3a 20.73.2a
Creatinine clearance mL/min/100 g 0.700.13 0.790.19 0.180.07a 0.160.10a
Plasma creatine lmol/L 12462 760410b 13495 935371b
Urinary creatine lmol/day 0.860.13 1537943b 0.630.05 1508788b
Total muscular creatine lmol/g 32.92.2 36.23.4b 33.12.0 36.02.4b
Urinary sulfate lmol/day/kg 106.313.3 98.218.2 140.241.9 114.167.4
aP  0.005, subtotal nephrectomized group vs. respective sham-operated control group
bP  0.05, creatine diet group vs. respective control diet–group
Fig. 2. Effect of creatine supplementation on total plasma homocys-
teine (tHcy) concentrations in sham-operated and subtotal nephrecto-
mized animals. Subtotal nephrectomized animals had significantly
higher tHcy concentrations than sham-operated animals. The creatine-
supplemented subtotal nephrectomized group had lower tHcy concen-
trations, compared to nephrectomized control diet–fed group. Creatine
supplementation in the sham-operated group did not lower tHcy con-
centrations significantly.
Plasma folate and vitamin B12 concentrations
No differences in plasma folate or vitamin B12 were
observed between nephrectomized and sham-operated
animals (Table 2). Plasma folate was higher in creatine-
supplemented groups [70.0 24.9 nmol/L vs. 40.8 17.6
nmol/L; P  0.001 (pooled data)]. No differences in
plasma vitamin B12 concentrations were observed be-
tween creatine-supplemented and control diet–fed ani-
mals [643  121 pmol/L vs. 618  165 pmol/L; P  NS
(pooled data)]. No significant correlation was observed
between plasma folate or vitamin B12 concentrations and
plasma tHcy concentrations. Plasma creatine concentra-
tion correlated significantly with plasma folate (r 0.47;
Fig. 3. Scatter diagram illustrating relation between plasma creatine
and total plasma homocysteine (tHcy) concentrations. tHcy concentra-
tions inversely correlated with plasma creatine concentrations. Data
from all groups are included in the graph.
Fig. 4. Effect of creatine supplementation on the correlation between
total plasma homocysteine (tHcy) concentrations and creatinine clear-
ance (mL/min). tHcy concentrations correlated with creatinine clear-
ance in control diet–fed animals, but the correlation was lost in creatine-
supplemented animals. Data from all groups are included in the graph.
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Table 2. Effect of creatine supplementation on plasma, hepatic folate, and vitamin B12 concentrations, in animals with with or without
preexisting renal failure
Sham-operated Subtotal nephrectomized
Control diet Creatine diet Control diet Creatine diet
(N  8) (N  8) (N  10) (N  10)
Plasma folate nmol/L 45.817.2 72.618.0b 38.018.2 67.531.3b
Plasma vitamin B12 pmol/L 521153 61062 672153 671155
Hepatic THF nmol/g 9.52.7 10.62.7 7.83.1 11.43.5b
Hepatic 5-CH3THF nmol/g 12.23.3 10.72.1 10.32.6 11.22.7
Hepatic vitamin B12 pmol/g 48.56.9 45.45.4 72.016.3a 67.917.6a
Abbreviations are: THF, tetrahydrofolate; 5-CH3THF, 5-methyltetrahydrofolate.
aP  0.05, subtotal nephrectomized group vs. respective sham-operated control group
bP  0.05, creatine diet group vs. respective control diet–group
P  0.01) but not with vitamin B12 (r  0.03; P  0.87)
concentrations.
Hepatic folate and vitamin B12 concentrations
Sham-operated and subtotal nephrectomized animals
had similar hepatic THF and 5-CH3THF concentrations.
Hepatic vitamin B12 concentrations were higher in sub-
total nephrectomized animals compared to sham-oper-
ated animals [7.0  1.7 pmol/g vs. 4.7  0.6 pmol/g; P 
0.002 (pooled data)]. Creatine-supplemented animals had
higher hepatic THF concentrations [11.1  3.2 nmol/g
vs. 8.6  2.9 nmol/g; P  0.02 (pooled data)]. Hepatic
5-CH3THF and vitamin B12 concentrations were compa-
rable between creatine-supplemented and control diet–
fed animals.
DISCUSSION
Uremic animals have higher tHcy than animals with
normal renal function, an observation in agreement with
the well-known high prevalence of hyperhomocysteine-
mia in patients with ESRD [19]. The correlation of
plasma tHcy with creatinine clearance in rats is in accor-
dance to literature [20]. The salient observation of the
present study is that oral creatine supplementation can
effectively lower plasma tHcy concentrations in animals
with uremia to normal tHcy concentrations. tHcy con-
centrations were 22% lower in the creatine-supple-
mented subtotal nephrectomized group, compared to the
control diet–fed group. Creatine supplementation in the
sham-operated animals did not lower tHcy significantly.
The latter observation is in line with the absence of an
effect of creatine supplementation on tHcy in young
healthy volunteers [21]. Hcy metabolism is tightly regu-
lated under normal conditions, whereas in situations with
compromised Hcy homeostasis, creatine supplementa-
tion might have a more direct and prominent tHcy low-
ering effect [22]. Species-related differences in metabolic
pathways could also explain the difference in effect be-
tween humans and rodents.
Plasma, urine, and muscle creatine concentrations were
higher in creatine-supplemented animals, documenting
uptake and metabolization of creatine in this animal
model. No difference in creatinine clearance was ob-
served between supplemented and control diet–fed ani-
mals in both sham-operated and nephrectomized ani-
mals. The safety of creatine supplementation and the
absence of adverse effects on renal function were pre-
viously assessed by our group in this animal model of
chronic renal failure [13]. No adverse effects on glomeru-
lar filtration or renal protein handling were observed.
However, adverse effects of creatine supplementation
on renal function have been reported. Edmunds et al
[23] demonstrated diminished creatinine clearance rates
and increased cyst formation in Han:SPRD-cy rats, an
animal model of human polycystic kidney disease. So
far, none of the controlled studies in humans on the
effects of creatine supplementation have indicated any
adverse effect [24]. However, safety of creatine supple-
mentation in subjects with preexisting renal failure re-
mains open for discussion.
Creatine supplementation was associated with higher
plasma folate concentrations and higher hepatic THF con-
centrations in the subtotal neprectomized group, whereas
folate intake was comparable in all groups. Higher folate
concentrations in the creatine-supplemented nephrecto-
mized animals reflect differences in folate metabolism,
as folic acid intake is comparable. Creatine supplementa-
tion lowers endogenous creatine synthesis and methyla-
tion demand, with lower Hcy formation. Remethylation
of Hcy to methionine might be diminished with an appar-
ent folate-saving effect. However, further research is re-
quired confirming these hypotheses, eventually using sta-
ble isotope protocols. In contrast to humans [25], no
relationship between urinary sulfate excretion and tHcy
was observed in our animal model, probably due to simi-
lar dietary intake of methionine and cysteine in all ani-
mals, accounting for comparable sulfate excretion.
The influence of creatine on labile methyl pool metab-
olism, and consequently on methionine Hcy cycling and
tHcy concentrations, has so far been underestimated.
Estimation of labile methyl pool consumption [10, 11]
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demonstrated that creatine biosynthesis accounts for up
to 70% of the methylation reactions in the human body.
The correlation between creatinine and tHcy concentra-
tions is attributable to two factors. First, both tHcy and
plasma creatinine depend on renal elimination. More-
over, creatine synthesis is intricately linked to Hcy for-
mation and creatine is degraded to creatinine. The corre-
lation observed between tHcy and creatinine is partly
due to glomerular filtration, but also due to creatine
creatinine conversion.
In humans, a low dietary intake of creatine is associ-
ated with higher tHcy concentrations. Vegetarians, con-
suming neglectable amounts of creatine, have higher
tHcy than subjects consuming an omnivorous diet [26–28],
even when vitamin B12 concentrations are similar [26].
Renal patients are generally kept on a low protein diet
with low dietary creatine intake. Endogenous creatine
synthesis and methylation demand could, therefore, be
higher in these patients, enhancing tHcy concentrations.
In middle-aged and elderly subjects, tHcy was found
to depend on gender with lower tHcy concentrations in
women than in men [29]. Gender transition studies in
male or female transsexuals have shown a strong depen-
dency of tHcy on creatinine concentrations. Male-to-
female transsexuals exhibited a substantial reduction in
tHcy and creatinine concentrations after estrogen and
antiandrogen therapy. Female-to-male transsexuals ex-
hibited higher tHcy and creatinine concentrations after
testosterone treatment. Taken together, these studies
suggest that Hcy production occurs in direct conjunction
with creatine synthesis [30].
Exogenous methylation demand, defined as increased
metabolic methyl group consumption by intake of sub-
stances (alimentary, drugs) requiring methylation during
their metabolization, can increase tHcy concentrations
by increasing methionine Hcy interconversion. The effect
of exogenous methylation demand on tHcy is illustrated
in Parkinson disease patients, treated with L-3,4-dihydroxy-
phenylalanine (L-DOPA). Metabolism of L-DOPA in-
volves the enzyme catechol-O-methyltransferase, with
S-adenosylmethionine as methyl group donor with for-
mation of S-adenosylhomocysteine. In Parkinson disease
patients treated with L-DOPA, plasma tHcy is higher
than in controls and untreated patients [31]. Increased
exogenous methylation demand is also observed with
the lipid-lowering agent niacin, which is metabolized and
excreted as methylated pyridones. High-dose niacin in-
take imposes a large methylation demand on the acti-
vated methyl cycle and increases tHcy concentrations and
decreases folate and vitamin B12 concentrations [32, 33].
CONCLUSION
The present study demonstrated that inhibition of en-
dogenous methylation demand with dietary creatine sup-
plementation can effectively lower tHcy in an animal
model of uremia. Creatine may thus have a promising
therapeutic potential in lowering tHcy concentrations
and reducing cardiovascular risk in ESRD patients. Fur-
ther research is required to examine whether the present
results can be extrapolated to humans with ESRD.
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